submitted by /u/mvea
[link] [comments]
Neurotrope shares crash after Alzheimer's drug fails in trial
Neurotrope shares crash after Alzheimer's drug fails in trial
Reuters: Health
Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.
Reuters: Health
Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.
U.S. judge denies bid to dismiss claim opioids are a public nuisance
U.S. judge denies bid to dismiss claim opioids are a public nuisance
Reuters: Health
The U.S. judge overseeing nationwide litigation concerning the opioid crisis on Monday rejected Purdue Pharma LP's effort to dismiss claims that its activities caused a public nuisance.
Reuters: Health
The U.S. judge overseeing nationwide litigation concerning the opioid crisis on Monday rejected Purdue Pharma LP's effort to dismiss claims that its activities caused a public nuisance.
China's Guangdong to release another 3,150 tonnes of pork from reserves to secure supplies
China's Guangdong to release another 3,150 tonnes of pork from reserves to secure supplies
Reuters: Health
China's Guangdong province said it will release 3,150 tonnes of frozen pork from reserves during the upcoming holidays, part of a campaign to secure supplies of the country's favorite meat, local media reported on Monday, after a devastating disease ravaged the hog herd.
Reuters: Health
China's Guangdong province said it will release 3,150 tonnes of frozen pork from reserves during the upcoming holidays, part of a campaign to secure supplies of the country's favorite meat, local media reported on Monday, after a devastating disease ravaged the hog herd.
Novartis CEO pledges to speed data integrity disclosures
Novartis CEO pledges to speed data integrity disclosures
Reuters: Health
Novartis Chief Executive Vas Narasimhan promised to inform U.S. regulators quickly if credible questions emerge internally over data integrity, he told investors on Monday, following data manipulation allegations involving the Swiss drugmaker's $2.1 million gene therapy Zolgensma.
Reuters: Health
Novartis Chief Executive Vas Narasimhan promised to inform U.S. regulators quickly if credible questions emerge internally over data integrity, he told investors on Monday, following data manipulation allegations involving the Swiss drugmaker's $2.1 million gene therapy Zolgensma.
Subscribe to:
Comments (Atom)
Subscribe UsPopular Posts
|